Literature DB >> 26323474

GO-QOL--disease-specific quality of life questionnaire in Graves' orbitopathy.

Nadia Sawicka-Gutaj1, Tomasz Bednarczuk, Jacek Daroszewski, Joanna Waligórska-Stachura, Piotr Miśkiewicz, Jerzy Sowiński, Marek Bolanowski, Marek Ruchała.   

Abstract

The main goal of therapy for Graves' orbitopathy (GO) is to restore visual function and to improve quality of life (QOL); therefore, the idea of self-assessment of eye changes by the patient has been developed. We developed a validated Polish version of the GO-QOL questionnaire (GO-QOLpl). As an original version we used the English version of GO-QOL, which consists of 15 questions summarised in two subscales. GO-QOLpl was translated and validated in accordance with standard principles for translation of patient-reported outcomes (PRO). GO-QOLpl is a linguistically validated version of the original GO-QOL questionnaire, which is recommended by the European Group of Graves' Orbitopathy (EUGOGO). We strongly support the use of GO-QOLpl for the assessment of QOL among Polish patients with GO in clinical practice.

Entities:  

Mesh:

Year:  2015        PMID: 26323474     DOI: 10.5603/EP.2015.0046

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  5 in total

1.  Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy.

Authors:  Luigi Bartalena; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2020-09-21

2.  Gender-dependent and age-of-onset-specific association of the rs11675434 single-nucleotide polymorphism near TPO with susceptibility to Graves' ophthalmopathy.

Authors:  Aleksander Kuś; Konrad Szymański; Beata Jurecka-Lubieniecka; Edyta Pawlak-Adamska; Dorota Kula; Piotr Miśkiewicz; Marek Bolanowski; Rafał Płoski; Artur Bossowski; Jacek Daroszewski; Barbara Jarząb; Tomasz Bednarczuk
Journal:  J Hum Genet       Date:  2016-11-10       Impact factor: 3.172

3.  PTX3: A Potential Biomarker in Thyroid Associated Ophthalmopathy.

Authors:  Pei Mou; Ziyu Chen; Lihong Jiang; Jinwei Cheng; Ruili Wei
Journal:  Biomed Res Int       Date:  2018-02-20       Impact factor: 3.411

4.  Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.

Authors:  Nadia Sawicka-Gutaj; Bartłomiej Budny; Ariadna Zybek-Kocik; Jerzy Sowiński; Katarzyna Ziemnicka; Joanna Waligórska-Stachura; Marek Ruchała
Journal:  Endocrine       Date:  2016-01-14       Impact factor: 3.633

5.  Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies.

Authors:  Nadia Sawicka-Gutaj; Mirosław Andrusiewicz; Agata Czarnywojtek; Joanna Waligórska-Stachura; Maciej Biczysko; Jerzy Skrobisz; Jerzy Sowiński; Marek Ruchała
Journal:  Biomed Res Int       Date:  2018-02-06       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.